Penumbra, Inc.· PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

• 

  Reasons to Retain Penumbra Stock in Your Portfolio for Now

  PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

  Sep 16, 2026
• 

  TFX vs. PEN: Which Stock Is the Better Value Option?

  Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

  Sep 11, 2026
• 

  Connor Clark & Lunn Investment Management Ltd. Buys New Position in Penumbra, Inc. $PEN

  Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Penumbra, Inc. (NYSE: PEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,111 shares of the company's stock, valued at approximately $1,614,000. A number of other institutional

  Aug 30, 2026

• EI

  Penumbra price target lowered to $320 from $335 at Evercore ISI

  Evercore ISI· Vijay Kumar· $320.00
  Jul 6, 2026
• EI

  Penumbra price target lowered to $335 from $345 at Evercore ISI

  Evercore ISI· Vijay Kumar· $335.00
  May 7, 2026
• UB

  UBS Reiterates Neutral Rating on Penumbra (PEN) Following Q4 Results

  UBS· Priya Sachdeva· $374.00
  Feb 26, 2026
• TF

  Truist Securities Downgrades Penumbra (PEN) to Hold

  Truist Financial· Richard Newitter· $374.00
  Jan 16, 2026
• LP

  Leerink Partners Downgrades Penumbra (PEN) to Market Perform

  Leerink Partners· Mike Kratky· $374.00
  Jan 16, 2026